Quality-Adjusted Time Without Symptoms or Toxicity Analysis of Adjuvant Chemotherapy in Non–Small-Cell Lung Cancer: An Analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 Trial

Jang, Raymond Woo-Jun; Maître, Aurélie Le; Ding, Keyue; Winton, Tim; Bezjak, Andrea; Seymour, Lesley; Shepherd, Frances A.; Leighl, Natasha B.

doi:10.1200/jco.2008.20.5815

Cited by 36 publications

(30 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The negative effects on HRQOL are temporary and improvement with a return to baseline function is likely in most patients. A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant vinorelbine and cisplatin given after resection of stage IB-II NSCLC showed that the adjuvant chemotherapy group had a statistically significant better Q-TWiST in the range of 5 to 6 additional months as compared with an observation-only group of patients [Jang et al 2009]. …”

Section: Lung Cancermentioning

confidence: 99%

Health-related quality of life and cancer clinical trials

2011

View full text Add to dashboard Cite

The measurement of patient-reported outcomes, including health-related quality of life, is a new initiative which has emerged and grown over the past four decades. Following the development of reliable and valid self-report questionnaires, health-related quality of life has been assessed in tens of thousands of patients and a wide variety of cancers. This review is based on a selection of data published in the last decade and is intended primarily for healthcare professionals. The assessments in clinical trials have been particularly useful for elucidating the effects of various cancers and their treatments on patients' lives and have provided additional information that enhances the usual clinical endpoints used for determining the benefits and toxicity of treatment. With growing experience the quality of the healthrelated quality of studies has improved and, in general, recent studies are more likely to be methodologically robust than those that were performed in earlier decades. Health-related quality of life has become a more accurate predictor of survival than some other clinical parameters, such as performance status. The overall outlook for the routine assessment of patient-reported outcomes in clinical trials is assured and, eventually, it is likely to become a standard part of clinical practice. However, there is still a need for a clear method for determining the clinical meaningfulness of changes in scores. The answer will probably come from the greater use of patient-reported outcomes and the consequent growth of experience that is necessary to make such judgements.

show abstract

Section: Lung Cancermentioning

confidence: 99%

Health-related quality of life and cancer clinical trials

2011

View full text Add to dashboard Cite

show abstract

“…This startling fact speaks to the molecular heterogeneity that exists between early stage tumors. Preoperative and adjuvant chemotherapies provide only modest benefits for patients and come with many side effects, thus biomarkers to predict which patients may benefit the most from additional therapies are needed [29] .…”

Section: Prognostic Mirnasmentioning

confidence: 99%

MicroRNA as tools and therapeutics in lung cancer

Barger

Nana‐Sinkam

2015

Respiratory Medicine

View full text Add to dashboard Cite

Lung cancer is the number one cause of cancer related deaths. The lack of specific and accurate tools for early diagnosis and minimal targeted therapeutics both contribute to poor outcomes. The recent discovery of microRNAs (miRNAs) revealed a novel mechanism for post-transcriptional regulation in cancer and has created new opportunities for the development of diagnostics, prognostics and targeted therapeutics. In lung cancer, miRNA expression profiles distinguish histological subtypes, predict chemotherapeutic response and are associated with prognosis, metastasis and survival. Furthermore, miRNAs circulate in body fluids and hence may serve as important biomarkers for early diagnosis or stratify patients for personalized therapeutic strategies. Here, we provide an overview of the miRNAs implicated in lung cancer, with an emphasis on their clinical utility.

show abstract

“…Utility values were derived from the literature for patients with and without ACT, SAEs with ACT, and for no cancer as well cancer recurrence [35][36][37][38].…”

Section: Literature-derived Inputsmentioning

confidence: 99%

Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer

et al. 2015

View full text Add to dashboard Cite

Background. A prognostic test was developed to guide adjuvant chemotherapy (ACT) decisions in early-stage non-small cell lung cancer (NSCLC) adenocarcinomas.The objective of this study was to compare the cost-utility of the prognostic test to the current standard of care (SoC) in patients with early-stage NSCLC. Materials and Methods. Lifetime costs (2014 U.S. dollars) and effectiveness (quality-adjusted life-years [QALYs]) of ACT treatment decisions were examined using a Markov microsimulation model from a U.S. third-party payer perspective. Cancer stage distribution and probability of receiving ACT with the SoC were based on data from an academic cancer center. The probability of receiving ACT with the prognostic test was estimated from a physician survey. Risk classification was based on the 5-year predicted NSCLC-related mortality. Treatment benefit with ACT was based on the prognostic score. Discounting at a 3% annual rate was applied to costs and

show abstract

Quality-Adjusted Time Without Symptoms or Toxicity Analysis of Adjuvant Chemotherapy in Non–Small-Cell Lung Cancer: An Analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 Trial

Cited by 36 publications

References 17 publications

Health-related quality of life and cancer clinical trials

Health-related quality of life and cancer clinical trials

MicroRNA as tools and therapeutics in lung cancer

Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About